Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue

Phase 2 Recruiting 25 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This is a phase 2b open-label trial to characterize histopathological biomarkers of disease in immunoglobulin A nephropathy (IgAN) and demonstrate potential changes in response to sibeprenlimab.

Timeline

Start: 2024-11-19
Primary completion: 2029-04-17
Completion: 2029-04-17

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sibeprenlimab	Monoclonal antibody	—	Subcutaneous

Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue

Summary

Timeline

Drugs

Indications